ATARA Biotherapeutics (ATRA) Receives Positive EMA Opinion on Orphan Drug Designation for CMV-CTL Product Candidate
- Wall St. rises amid robust earnings, GDP data
- FBI to review more emails related to Clinton's private email use: letter
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that the European Medicines Agency (EMA) issued a positive opinion for orphan drug designation for the Company's CMV-CTL product candidate for the treatment of CMV infection in patients with impaired cell-mediated immunity.
"The positive opinion from EMA to designate CMV-CTLs as an orphan medicinal product in the European Union (EU) demonstrates the compelling need for new treatments to combat this viral infection in patients with few therapeutic options," said Isaac Ciechanover, M.D., President and Chief Executive Officer of Atara Bio. "We look forward to the presentation of additional clinical data at upcoming scientific congresses on the use of CMV-CTL to treat refractory CMV infection in patients who have received an allogeneic hematopoietic cell transplant, and to continuing our discussions with both FDA and EMA on late phase development to support registration of CMV-CTL."
Orphan drug designation in the EU provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating conditions affecting no more than five in 10,000 persons in the EU, and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase and direct access to the centralized procedure for authorizing medicinal products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- St. Jude Medical (STJ) Announces FDA Approval, U.S. Launch of Medical Device to Reduce Risk of Recurrent Ischemic Stroke in Patients with PFO
- Quantenna Communications (QTNA) Prices 6.7M Common Stock IPO at $16/Share, at Upper-End of Expected Range
- European Commission Opens Investigation into Proposed Acquisition of Syngenta (SYT) by ChemChina
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!